Regenerative Cell Therapies for Neurodegenerative Diseases

NeuroGenesis is a clinical-stage biotechnology company.
We are advancing innovative cell therapies via our propriety NEURALyzed CELL™ platform to combat neurodegenerative diseases.

PLATFORM

ABOUT US

Milestones

Hadassah researchers-initiated Phase I/II

(MS & ALS – 34 Patients)

Published results of Phase I/II

Published Long term Study results (MS – 28 Patients)

Initiated Phase IIA – Progressive MS (48 Patients)
Initiated compassionate treatments (MS , ALS)

Received EU patent

Company established - License from Hadasit & Seed capital

Phase IIB - Unprecedented Interim Results

Publish Phase IIB results – ECTRIMS 2019 Conference

Science

NG-01-MS has been manufactured for treating MS & ALS patients for over 15 years. Trials were investigator initiated and regulated by the Israeli Mistry of Health and local IRB. NeuroGenesis was founded to clinically develop this product.

​

NG-1 is the company’s lead product. The intended indication of NG-1 is for the treatment of progressive Multiple Sclerosis.

NG-1 has neuroprotective and neuro-regenerative properties. NG-1 can prevent neurons and oligodendrocytes from apoptosis via the release of trophic and anti-apoptotic molecules (NGF, BDNF, and others), and have anti-proliferative effects on microglial cells and astrocytes, resulting in the induction of a neuroprotective microenvironment.

NG-1 also promotes the proliferation and maturation of local neural precursor cells, leading to their differentiation into mature neurons and oligodendrocyte.